- BioMatrix Healthcare has acquired a greenfield API manufacturing facility with R&D capabilities in Vadodara, India.
- The acquisition strengthens backward integration, supply chain resilience, and end-to-end CDMO services.
BioMatrix Healthcare has announced the acquisition of a greenfield active pharmaceutical ingredient (API) manufacturing facility with research and development capabilities in Vadodara, India, as part of its growth strategy.
The transaction expands the company’s manufacturing footprint and strengthens backward integration across its operations. BioMatrix stated that the addition is intended to improve supply chain resilience while enhancing its contract development and manufacturing organisation (CDMO) services.
With the new facility, BioMatrix aims to support partners across the full product lifecycle, from API development and drug master file filing through to finished dosage form manufacturing.
BioMatrix noted that the expansion will enable it to deliver greater value to global partners by focusing on quality, scalability and regulatory compliance.
